Navigation Links
Allergic reactions to gadolinium-based contrast agents are rare, study finds
Date:12/28/2007

Allergic-like reactions to gadolinium-containing contrast injections in adults and pediatric patients (those younger than 19 years of age) are rare, according to a recent study conducted by researchers at the University of Michigan Health Systems in Ann Arbor. When these reactions do occur, most of them are mild, said Jonathan R. Dillman, MD, lead author of the study.

Over the past few years, the utilization of contrast-enhanced MRI has markedly increased; its increased by 65% at our institution over the previous five years, said Dr. Dillman.. This is due, at least in part, to a variety of new applications, such as magnetic resonance angiography (MRA) and abdominopelvic MR imaging, he said. Consequently, the number of intravenously administered gadolinium-containing contrast material doses over the same time period has significantly increased. Based on the extensive use these intravascular contrast agents, we felt that it was once again time to study their safety profile, he said.

The study included 78,353 gadolinium-containing contrast injections over a five year period. Acute allergic-like reactions occurred following 54 injections. According to the study, 48 reactions involved adults and six occurred in pediatric patients. The study showed that 74% of these reactions were mild, 19% were moderate, and 7% were severe.

Despite recent concerns that have emerged about the gadolinium-based contrast agents and the development of nephrogenic systemic fibrosis in patients who have severe chronic kidney disease, our study supports the long-held belief that gadolinium based contrast agents can be used safely in both pediatric and adult patients with normal or with only mildly impaired renal function, said Dr. Richard Cohan, co-author of the study. The risk of allergic-like reactions is exceedingly low (0.07% of administrations in our study), and no fatal reaction occurred at our institution in more than 78,000 intravenous administrations. Patients should feel reassured, based on our results, that the intravenous gadolinium-contrast agents included in our study are quite safe when administered to patients with ample renal function, he said.

The full results of this study appear in the December issue of the American Journal of Roentgenology, published by the American Roentgen Ray Society.


'/>"/>
Contact: Necoya Tyson
necoya@arrs.org
703-858-4304
American Roentgen Ray Society
Source:Eurekalert

Related medicine news :

1. Role seen for cannabis in helping to alleviate allergic skin disease
2. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
3. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
4. Protein suppresses allergic response in mice
5. Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid
6. London School of Hygiene to play key role in global collaboration on adverse drug reactions
7. DOCTORS OPPOSE MARYLAND VACCINE ROUNDUP: Expect Dangerous Reactions When Children Are Treated Like Cattle
8. MDs reactions to pharma marketing influenced by brand, side effects: Management Insights
9. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
10. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
11. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... Learn to use popular ... or even in relationships. Course offered by Dr. Carol Francis at PVNET on ... limited seating and the many hands-on experiences. , Dr. Carol Francis shows ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... that its annual Solutions Series of webinars will start January 31 with a ... a number of current health and benefits topics, including employee engagement, pricing transparency, ...
(Date:1/24/2017)... ... January 24, 2017 , ... Bellus Medical, a leader in medical ... experts. In his new role Dr. Dobke will provide physician oversight for in-house clinical ... the Head of Plastic Surgery and Associate Professor of Surgery at UC San Diego ...
(Date:1/24/2017)... N.C. (PRWEB) , ... January 24, 2017 , ... ... Administration is the focus of a new report from the Frank Hawkins ... Business School. , Influential business leaders, academics and policy makers identified concrete solutions ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the ... everyone and particularly good news for prostate cancer patients: incidents of cancer is down ... to the report the cancer death rate has dropped from its peak of 215.1 ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 2017 Sherpa Clinical Packaging ( www.sherpaclinical.com ... is pleased to announce the appointment of Kevin Rosenthal as ... Sherpa team to lead Sherpa,s Operations group and ... excellence. Kevin is not new to ... He has extensive experience working for leading pharma ...
(Date:1/24/2017)... and PUNE, India , January 24, 2017 ... Allied Market Research, titled, "Acidity Regulators Market - Global ... for acidity regulators was valued at $4,456 million in 2015, and ... CAGR of 7.96% from 2016 to 2022. Asia-Pacific ... maintain its lead, followed by North America ...
(Date:1/24/2017)... , January 24, 2017 ... value of USD 3.8 billion by 2025, according to ... market growth can be attributed to the rising initiatives ... early diagnosis of micro calcifications in breast tissue. Some ... CDC, and Breast Cancer Organization are promoting the early ...
Breaking Medicine Technology: